Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma

This phase II randomized trial compares the efficacy and safety of Toripalimab combined with three different platinum-based induction chemotherapy regimens, sequentially followed by standard concurrent chemoradiotherapy, for the treatment of locally advanced nasopharyngeal carcinoma (NPC). The study is aimed to pick up the most effective platinum-based induction chemotherapy regimen plus Toripalimab for these patients which provides the most survival benefit.

Trial Details

NCT ID
NCT07362979
Phase
PHASE2
Sponsor
Sun Yat-sen University
Status
RECRUITING
Cancer Type
Nasopharyngeal Head and Neck Cancer
Interventions
  • GP plus Toripalimab Induction chemotherapy+CCRT
  • TP plus Toripalimab Induction chemotherapy+CCRT
  • TPC plus Toripalimab Induction chemotherapy+CCRT
Locations (sample)
  • Dongguan, Guangdong, China|23.01797,113.74866
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Shenzhen, Guangdong, China|22.54554,114.0683
  • Zhanjiang, Guangdong, China|21.23391,110.38749

Key Eligibility Criteria

  • Age between 18 and 70 years, male or non-pregnant female.
  • Pathologically confirmed nasopharyngeal non-keratinizing carcinoma (differentiated or undifferentiated type, i.e., WHO type II or type III).
  • Stage Any T, N2-3 or T4, N1 (AJCC 9th edition staging), with no distant metastasis (M0).
  • ECOG performance status score of 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Nasopharyngeal Head and Neck Cancer Trials on Trialify →